Swirsky Douglas J 4
4 · Cellectar Biosciences, Inc. · Filed Jul 8, 2026
Research Summary
AI-generated summary of this filing
Cellectar (CLRB) Director Douglas Swirsky Receives 37,500-Share Award
What Happened
Douglas J. Swirsky, a director of Cellectar Biosciences, was granted a derivative award for 37,500 shares on July 7, 2026. The grant is reported at $0.00 per share (no cash paid at grant). The award is a compensated equity grant rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-07-07; Form 4 filed: 2026-07-08 (timely filing).
- Instrument: Derivative award/option-type grant for 37,500 shares reported at $0.00.
- Vesting: The award "shall vest in full on July 7, 2027," subject to continued service (footnote).
- Shares owned after transaction: Not specified in this Form 4.
- Filing timeliness: Filed the next calendar day (no late-file indication).
Context
This is a compensation-related equity grant typical for directors; it is not an open-market purchase or sale and does not by itself signal buying or selling intent. As a derivative award, its eventual value to the insider depends on future vesting and Cellectar’s stock price at the time of vesting or conversion.
Insider Transaction Report
Form 4
Swirsky Douglas J
Director
Transactions
- Award
Stock option (right to buy)
[F1]2026-07-07+37,500→ 37,500 totalExercise: $2.70Exp: 2036-07-07→ Common stock (37,500 underlying)
Footnotes (1)
- [F1]This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.
Signature
/s/ Chad Kolean, attorney-in-fact for Douglas Swirsky|2026-07-08